Coexpression of Stromelysin-3 and Insulin-Like Growth Factor II in Tumors of Ectodermal, Mesodermal, and Endodermal Origin

Indicator of a Fetal Cell Phenotype

Christian F. Singer, Audrey Rasmussen, Marc E Lippman, Kevin J. Cullen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Stromelysin-3 (ST-3) is thought to play an important role in invasion and tumor progression. We have analyzed ST-3 expression in fibroblasts with defined topographical relations to breast cancers. We demonstrate that these fibroblasts exhibit the same distinctive pattern of messenger ribonucleic acid (mRNA) expression that we have previously shown for insulin-like growth factor II (IGF-II). Tumor-derived fibroblasts and skin fibroblasts produce abundant ST-3 mRNA. Fibroblasts from normal breast stroma distant from the malignant tumor in the same patient express considerably less ST-3 mRNA. When we analyzed ST-3 and IGF-II gene expression in sarcomas, we found a similar pattern of coexpression. Immunohistochemical analysis of IGF-II and ST-3 protein expression in sarcomas and breast tumors confirmed the mRNA data. ST-3 mRNA expression was also seen in most colon cancer cell lines, again matching reports of IGF-II gene expression. As the two proteins are known to play an important role during fetal growth and development, their coexpression in fibroblasts from malignant tumors of ectodermal (breast cancer) and mesodermal (sarcoma) origin and in epithelial cells of endodermal origin (colon cancer) implies a more primitive cellular phenotype. The regained ability to express such developmentally regulated proteins might, therefore, be a more general marker indicating a fetal-type phenotype of cells in a malignant tumor.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume82
Issue number6
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 11
Insulin-Like Growth Factor II
Fibroblasts
Tumors
Phenotype
RNA
Neoplasms
Sarcoma
Breast Neoplasms
Fetal Development
Gene expression
Colonic Neoplasms
Gene Expression
Proteins
Growth and Development
Skin
Breast
Epithelial Cells
Cells
Cell Line

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Coexpression of Stromelysin-3 and Insulin-Like Growth Factor II in Tumors of Ectodermal, Mesodermal, and Endodermal Origin : Indicator of a Fetal Cell Phenotype. / Singer, Christian F.; Rasmussen, Audrey; Lippman, Marc E; Cullen, Kevin J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 6, 01.12.1997, p. 1917-1922.

Research output: Contribution to journalArticle

@article{22951645baca4cd29a063399b16625af,
title = "Coexpression of Stromelysin-3 and Insulin-Like Growth Factor II in Tumors of Ectodermal, Mesodermal, and Endodermal Origin: Indicator of a Fetal Cell Phenotype",
abstract = "Stromelysin-3 (ST-3) is thought to play an important role in invasion and tumor progression. We have analyzed ST-3 expression in fibroblasts with defined topographical relations to breast cancers. We demonstrate that these fibroblasts exhibit the same distinctive pattern of messenger ribonucleic acid (mRNA) expression that we have previously shown for insulin-like growth factor II (IGF-II). Tumor-derived fibroblasts and skin fibroblasts produce abundant ST-3 mRNA. Fibroblasts from normal breast stroma distant from the malignant tumor in the same patient express considerably less ST-3 mRNA. When we analyzed ST-3 and IGF-II gene expression in sarcomas, we found a similar pattern of coexpression. Immunohistochemical analysis of IGF-II and ST-3 protein expression in sarcomas and breast tumors confirmed the mRNA data. ST-3 mRNA expression was also seen in most colon cancer cell lines, again matching reports of IGF-II gene expression. As the two proteins are known to play an important role during fetal growth and development, their coexpression in fibroblasts from malignant tumors of ectodermal (breast cancer) and mesodermal (sarcoma) origin and in epithelial cells of endodermal origin (colon cancer) implies a more primitive cellular phenotype. The regained ability to express such developmentally regulated proteins might, therefore, be a more general marker indicating a fetal-type phenotype of cells in a malignant tumor.",
author = "Singer, {Christian F.} and Audrey Rasmussen and Lippman, {Marc E} and Cullen, {Kevin J.}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "82",
pages = "1917--1922",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Coexpression of Stromelysin-3 and Insulin-Like Growth Factor II in Tumors of Ectodermal, Mesodermal, and Endodermal Origin

T2 - Indicator of a Fetal Cell Phenotype

AU - Singer, Christian F.

AU - Rasmussen, Audrey

AU - Lippman, Marc E

AU - Cullen, Kevin J.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Stromelysin-3 (ST-3) is thought to play an important role in invasion and tumor progression. We have analyzed ST-3 expression in fibroblasts with defined topographical relations to breast cancers. We demonstrate that these fibroblasts exhibit the same distinctive pattern of messenger ribonucleic acid (mRNA) expression that we have previously shown for insulin-like growth factor II (IGF-II). Tumor-derived fibroblasts and skin fibroblasts produce abundant ST-3 mRNA. Fibroblasts from normal breast stroma distant from the malignant tumor in the same patient express considerably less ST-3 mRNA. When we analyzed ST-3 and IGF-II gene expression in sarcomas, we found a similar pattern of coexpression. Immunohistochemical analysis of IGF-II and ST-3 protein expression in sarcomas and breast tumors confirmed the mRNA data. ST-3 mRNA expression was also seen in most colon cancer cell lines, again matching reports of IGF-II gene expression. As the two proteins are known to play an important role during fetal growth and development, their coexpression in fibroblasts from malignant tumors of ectodermal (breast cancer) and mesodermal (sarcoma) origin and in epithelial cells of endodermal origin (colon cancer) implies a more primitive cellular phenotype. The regained ability to express such developmentally regulated proteins might, therefore, be a more general marker indicating a fetal-type phenotype of cells in a malignant tumor.

AB - Stromelysin-3 (ST-3) is thought to play an important role in invasion and tumor progression. We have analyzed ST-3 expression in fibroblasts with defined topographical relations to breast cancers. We demonstrate that these fibroblasts exhibit the same distinctive pattern of messenger ribonucleic acid (mRNA) expression that we have previously shown for insulin-like growth factor II (IGF-II). Tumor-derived fibroblasts and skin fibroblasts produce abundant ST-3 mRNA. Fibroblasts from normal breast stroma distant from the malignant tumor in the same patient express considerably less ST-3 mRNA. When we analyzed ST-3 and IGF-II gene expression in sarcomas, we found a similar pattern of coexpression. Immunohistochemical analysis of IGF-II and ST-3 protein expression in sarcomas and breast tumors confirmed the mRNA data. ST-3 mRNA expression was also seen in most colon cancer cell lines, again matching reports of IGF-II gene expression. As the two proteins are known to play an important role during fetal growth and development, their coexpression in fibroblasts from malignant tumors of ectodermal (breast cancer) and mesodermal (sarcoma) origin and in epithelial cells of endodermal origin (colon cancer) implies a more primitive cellular phenotype. The regained ability to express such developmentally regulated proteins might, therefore, be a more general marker indicating a fetal-type phenotype of cells in a malignant tumor.

UR - http://www.scopus.com/inward/record.url?scp=0031156702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031156702&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 1917

EP - 1922

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -